OpenAI to acquire Orchestra Bio to expand into life sciences R&D
The acquisition aims to integrate AI-driven operations into biopharma workflows to accelerate drug development timelines.
Trust78
HypeLow hype
1 source · single source
- OpenAI announced plans to acquire Orchestra Bio, a company focused on AI-powered operations for life sciences research and development.
- The deal is intended to help biopharma teams streamline drug development and advance new treatments.
- No financial terms or completion timeline were disclosed in the announcement.
OpenAI said it will acquire Orchestra Bio, a company that develops AI-powered operations for life sciences research and development. The acquisition is intended to bring AI-driven tools to biopharma teams to help accelerate drug development and advance new treatments. The announcement did not disclose financial terms or a completion timeline for the deal.
- Oct 20, 2026 · TechCrunch — AI
Eric Schmidt’s Anthropic stake reported at about 1%, roughly half of CEO Dario Amodei’s share
Trust75 - Oct 20, 2026 · The Verge — AI
CoreWeave’s distressed debt sparks broader unease over AI infrastructure financing
Trust74 - Oct 19, 2026 · TechCrunch — AI
Anthropic commits 5% of shares to a public benefit fund, with potential for additional contributions tied to valuation
Trust78